Edgewise Therapeutics, Inc. (EWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put EWTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS remains positive in 2026 with improvement from prior losses: Comparison needs review.
View ThesisThis stock is volatile — it swings about 2% on a typical day and fell roughly 25% in its worst 12-month stretch.
View RiskEWTX’s cardiovascular pipeline, including EDG-7500 and EDG-15400, is the central growth claim. Recent performance is weak, with Q2 FY2026 GAAP EPS missing consensus by 10.4%. The price is roughly in line with forecast growth, but no clean valuation multiple anchors the comparison. Our model puts the next-quarter miss probability near 39%. The thesis pillar is under pressure, though the stated EPS comparison needs review. Peer multiples imply a price about 24% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. EWTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering EWTX (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for EWTX in the last 4 months.
Continue this research
Compare EWTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EWTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EWTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance cardiovascular pipeline with EDG-7500 and EDG-15400
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $38.90
The last 12 months of price, then the range of analyst 12-month targets from today’s $38.90.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Differentiated mechanism supports cardiovascular pipeline advancement.
